“ Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors - a single center experience ” (2015) Clinics, 70(8), pp. 550–555. doi:10.6061/clinics/2015(08)04.